Search

everythinglearnresearchcommunity

for

Search:↓

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

Budesonide is not effective for maintaining remission in Crohn's disease beyond three months.

A woman with rheumatoid arthritis lost all her hair during adalimumab treatment, and stopping the drug didn't help.

A CCS patient with severe complications was successfully treated using combined therapies.

The 595-nm pulsed dye laser effectively reduces symptoms of EFFC with minimal side effects.

A Japanese man with rare skin conditions improved with hydroxychloroquine treatment.

Telitacicept helped stabilize complement levels in a patient with lupus and thyroid cancer.

PX-12 may help treat psoriasis by blocking inflammation and cell death.

Tofacitinib helped improve symptoms and hair growth in a patient with Aicardi-Goutières syndrome.

Tofacitinib helped a young woman's severe hair loss and arthritis but not her plaque psoriasis.

Chronic cutaneous lupus erythematosus should be considered when acne treatments don't work.

Co-trimoxazole successfully treated a girl with multiple autoimmune symptoms.

A rare scalp condition was successfully treated with specific medications after 9 months.

Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.

Leflunomide and anthralin may effectively treat severe alopecia areata.

Baricitinib might help treat hair loss in lupus patients, but more research is needed.

The oral contraceptive ethinylestradiol/chlormadinone acetate is effective in reducing acne and improving other skin conditions related to high androgen levels.

The 308-nm excimer laser is a promising treatment for vitiligo with varying success and mild side effects.

A sick foal with Rhodococcus equi pneumonia was successfully treated for multiple complications with targeted therapy and careful monitoring.

Secukinumab can cause hair loss, which may improve after stopping the medication.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

Biologic agents can be effective for rheumatic diseases but have risks like infections and require careful monitoring and patient information.

Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.

Most patients successfully switched from the original adalimumab to a biosimilar with few reverting due to reduced effectiveness or side effects.

Dupilumab may worsen Alopecia Areata in some males but improve it in some females, suggesting personalized treatment is needed.

Pembrolizumab can cause serious liver issues, requiring close monitoring and early treatment.

ALA-PDT is effective and safe for chronic X-ray dermatitis, providing complete or partial remission.